drugset / Trial / NCT01035580

Trial on Safety and Pharmacokinetics of Intravaginal Curcumin

NCT01035580

Phase 1 Completed 13 enrolled Emory University
NaSingle-groupOpen-labelTreatment

Summary

The main objective of this study is to determine the maximum tolerable dose and safety of intravaginal curcumin in a normal population of women (women with no evidence of cervical cytological abnormalities by pap testing).

Timeline

Start
2010-01
Primary completion
2011-04
Completion
2012-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Curcumin Small molecule 500 mg Other
Subject Curcumin Small molecule 1000 mg Other
Subject Curcumin Small molecule 1500 mg Other
Subject Curcumin Small molecule 2000 mg Other

Indications